Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorene SCHEMBL23748030 | 0.79 | SRD5A2 (0.39) | SMN1; SMN2 | |
| SCHEMBL6059544 | 0.77 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL4326668 | 0.77 | ALDH1A1 (0.36) | — | |
| SCHEMBL5877940 | 0.77 | ALOX15 (0.30) | — | |
| SCHEMBL868200 | 0.77 | — | — | |
| SCHEMBL9980489 | 0.75 | NAAA (0.35) | — | |
| SCHEMBL23355066 | 0.75 | KDM2A (0.33) | SMN1; SMN2 | |
| SCHEMBL2726401 | 0.74 | RECQL (0.30) | — | |
| SCHEMBL4786240 | 0.74 | TRPA1 (0.34) | — | |
| SCHEMBL6025638 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001062827-A2 | N-MALEIMIDYL POLYMER DERIVATIVES | SHEARWATER CORPORATION (US) | 2001-08-30 | — | — | WO | claimed |
| EP-3946460-B1 | IMPROVED CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260007768-A1 | CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4587583-A1 | COVALENTLY MODIFIED TEMPLATE-INDEPENDENT DNA POLYMERASE AND METHODS OF USE THEREOF | The Charles Stark Draper Laboratory, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12364771-B2 | Conjugation linkers | PROLYNX LLC (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240181397-A1 | HIGH-THROUGHPUT MICROEMULSIFICATION MEMBRANE | PROLYNX LLC (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024059703-A1 | COVALENTLY MODIFIED TEMPLATE-INDEPENDENT DNA POLYMERASE AND METHODS OF USE THEREOF | THE CHARLES STARK DRAPER LABORATORY, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4308649-A2 | HIGH-THROUGHPUT MICROEMULSIFICATION MEMBRANE | Prolynx LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2023091618-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF OVARIAN CANCER | MERCY BIOANALYTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2003037384-A2 | POLYMER CONJUGATES OF PROTEIN KINASE C INHIBITORS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20030066988-A1 | Malononitrile-derivative anion salts, and their uses as ionic conducting materials | MICHOT CHRISTOPHE (FR) | 2003-04-10 | — | — | US | disclosed |
| EP-1259562-A1 | STERICALLY HINDERED DERIVATIVES OF WATER SOLUBLE POLYMERS | Shearwater Corporation (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002065963-A1 | BIODEGRADABLE CATIONIC COPOLYMERS OF POLY(ALKYLENIMINE) AND POLY(ETHYLENE GLYCOL) FOR THE DELIVERY OF BIOACTIVE AGENTS | EXPRESSION GENETICS, INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002040058-A2 | HYDROXYAPATITE-TARGETING POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS | SHEARWATER CORPORATION (US) | 2002-05-23 | — | — | WO | disclosed |
| US-6333425-B1 | IONIC COMPOUNDS DERIVED FROM MALONONITRILE IN WHICH ANIONIC CHARGE IS DELOCALIZED; EXCELLENT PROPERTIES OF SOLUBILITY AND DISSOCIATION | HYDRO-QUEBEC (CA) | 2001-12-25 | — | — | US | disclosed |
| WO-2001062827-A2 | N-MALEIMIDYL POLYMER DERIVATIVES | SHEARWATER CORPORATION (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001046291-A1 | STERICALLY HINDERED DERIVATIVES OF WATER SOLUBLE POLYMERS | SHEARWATER CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1105730-A1 | ENZYME INHIBITION IMMUNOASSAY | Roche Diagnostics Corporation (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001001135-A1 | ENZYME INHIBITION IMMUNOASSAY | ROCHE DIAGNOSTICS CORPORATION (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | SMN1; SMN2 2386/4885 |
| US-20260007768-A1 | CONJUGATION LINKERS | OGFR, SLC43A1, ILK | SMN1; SMN2 3755/4885 |
| US-12364771-B2 | Conjugation linkers | DNPEP, FGB, VIP | SMN1; SMN2 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.